mash tirzepatide Eli Lilly's Shows Promise in Treating Fatty Liver Disease Nearly 62% achieve MASH resolution

Mar 2000;114(3):207-9

If the color shifts noticeably from the initial appearance, treat the vial as potentially degraded and consult the supplier for guidance rather than continuing use

Less than 3% of clinical trial participants experienced persistent diarrhea beyond week 16, and most of those found it manageable enough to continue treatment

For patients who plateau, switching medications can reignite progress

Rather than abandoning GLP-1 therapy, these patients may benefit from switching medications, adding complementary compounds, or using PlexusDx's GLP-Squared dual-compound protocol that combines semaglutide and tirzepatide